EP Patent

EP0907642B1 — Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases

Assigned to Pfizer Inc · Expires 2005-11-02 · 21y expired

What this patent protects

The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts thereof, wherein R?1, R2, R3, R4¿, n and Z are as defined herein. The compounds of formula (I) are useful in the treatment of hyperproliferative disorders, such as cancer. The invention als…

USPTO Abstract

The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts thereof, wherein R?1, R2, R3, R4¿, n and Z are as defined herein. The compounds of formula (I) are useful in the treatment of hyperproliferative disorders, such as cancer. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and to methods of treating hyperproliferative disorders using the compounds of formula (I).

Drugs covered by this patent

Patent Metadata

Patent number
EP0907642B1
Jurisdiction
EP
Classification
—
Expires
2005-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.